Pregabalin Capsule
Product Images NDC 50228-352

Product Visual Gallery

This gallery contains 37 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50228-352). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (100 mg Capsule Blister Pack)

This is a description of a medication called Pregabalin available in capsule form. The capsules must be stored at a temperature of around 25°C (77°F) and allowed to have excursions between 15-30°C (59-86°F). They must be kept in tight, child-resistant containers. No dosage or usage information is provided apart from advice to see accompanying prescribing information. Each capsule contains 100mg of pregabalin. The medication is produced by a company called Stein Pharmaceuticals, based in Hauppauge, NY. The product comes in a pack of 1000 capsules with a lot number provided. This is useful information for medical professionals who prescribe, dispense or administer the medication.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

This text describes details about the storage, dispensing and dosage information of Pregabalin capsules. It mentions the permitted temperature range for storage, the importance of using tight and child-resistant containers for dispensing it, and the quantity of the medicine in each capsule. The text also provides a revision number, the NDC code, and the manufacturer of the medicine. It instructs users to refer to the accompanying prescribing information as well as the medication guide for dosage and use. It includes a disclaimer that mentions a "NO VARNISH AREA".*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle)

Each capsule of this medication contains 100mg of pregabalin, also known as Wuenne. It is important to store this medication at a temperature between 15°C and 30°C (59°F to 86°F). The medication should be dispensed in tightly sealed and child-resistant containers, along with an accompanying medication guide for each patient. This is a prescription-only medication and is manufactured by SciaGen Pharmaceuticals in Hauppauge, NY.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle Label)

This is a description of Pregabalin capsules manufactured by Sclen Pharmaceuticals. It contains 150 mg of Pregabalin per capsule and should be dispensed in tight, child-resistant containers. It can be stored at controlled room temperature between 25°C-30°C (39-86°F). Dosage and usage information can be found in the accompanying prescribing information, and the product comes in a box containing 1,000 capsules labeled NG 50228-354-10. The text also includes a revision date of 01/16.*

FDA Label Image

Principal Display Panel (150 mg Capsule Blister Pack Carton)

Store these pregabalin capsules containing 150mg of pregabalin at 25°C (77°F) with excursions allowed to 1510.30°C (50t 8E°F) [see USP Controlled Room Temperature]. Dispense these capsules in tight (USP), child-resistant containers. The dosage and usage instructions are available in the prescribing information that accompanies the product. This product comes in a pack containing 30 capsules with the NDC 50228-354-30. The manufacturer of this medication is Sdeen Parmceutas, located in Hauppauge Y 11768.*

FDA Label Image

Principal Display Panel (150 mg Capsule Blister Pack Carton)

Each capsule contains 150mg of pregabalin. It is recommended to store the medication at 25°C (77°F) with excursions allowed between 15°C to 30°C (59°F to 86°F). Dispense in tight and child-resistant containers with the medication guide included for each patient. The LD 90 Capsules are for prescription use only and are manufactured by ScieGen Pharmaceuticals, Inc. located in Hauppauge, NY 11788.*

FDA Label Image

Principal Display Panel (200 mg Capsule Blister Pack)

This text provides instructions for the storage and dispensing of 200 mg pregabalin capsules, which should be stored at 77°F but can be kept at temperatures between 50-86°F. The medication should be dispensed in tight, child-resistant containers, and dosage and use should follow the accompanying prescribing information. The capsules come in a bottle of 30 and are only available with a prescription. The manufacturer is SieGen Pharmaceuticals located in Hauppauge, WV 11788.*

FDA Label Image

Principal Display Panel (200 mg Capsule Blister Pack Carton)

This is a description of a medication called Pregahal, which comes in capsules containing 200mg of pregabaln. The medication should be stored at a temperature of 25°C (77°F), but excursions are permitted to a range of 15–30°C (59-86°F) controlled by USP. The capsules should be kept in tight, child-resistant containers. Dosage and usage information can be found in the accompanying prescribing information. The text also includes a revision date of 01/16 and a product number of NOC 50228-355-05.*

FDA Label Image

Principal Display Panel (200 mg Capsule Blister Pack)

This is a medication called Pregabalin, which comes in a capsule containing 200 mg. The recommended storage temperature for this medication is between 15°C and 30°C. It should be kept in a tight container and accompanied by a medication guide to be given to each patient. The manufacturer is ScieGen Pharmaceuticals, Inc., located in Hauppauge, NY.*

FDA Label Image

Principal Display Panel (225 mg Capsule Bottle Label)

This is a medication label for Pregabalin capsules containing 205mg of the drug. Storage of the medication is recommended at 25°C, with excursions permitted to 15-30°C, and the medicine should be dispensed in tight, child-resistant containers. The product is only available through a prescription, and patients should consult the prescribing information before use. The label also displays the manufacturer's details, NDC number, and manufacturing revision date.*

FDA Label Image

Principal Display Panel (225 mg Capsule Bottle Label)

This is a medication container of Pregabalin capsules containing 225 mg each. The container should be stored at room temperature not exceeding 30°C and in tight child-resistant packaging. The dosage and usage information are not available. The packaging also shows the manufacturer's name and revision date.*

FDA Label Image

Principal Display Panel (225 mg Capsule Bottle Label)

Each capsule contains 225 mg of pregabalin. Store at room temperature, between 15°C and 30°C (59°F and 86°F). Dispense in tightly sealed, child-resistant containers, and provide the accompanying medication guide to each patient. This medication is only available by prescription, with 90 capsules per container. Manufactured by ScieGen Pharmaceuticals, Inc. in Hauppauge, NY 11788.*

FDA Label Image

Principal Display Panel (25 mg Capsule Blister Pack)

This is a description of Pregabalin capsules manufactured by SclGen Pharmaceuticals. The capsules contain 25mg of Pregabalin and come in chill-resistant containers. The drug is stored at room temperature with excursions permitted to 30°C. Dosage and usage instructions can be found in the accompanying prescribing information. The NDC number for these capsules is 50228-350-10. The text also includes a revision date of January 2016.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

This is a prescription drug containing 25 mg of pregabalin per capsule. It should be stored at room temperature and protected from temperature excursions. Dispense in a tightly sealed and chill-resistant container. A medication guide should be dispensed along with the drug to each patient. DOSAGE AND USE instructions should be followed as per the accompanying prescribing information. This drug is manufactured by L0 Sieen Pharmaceuticals.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle)

This is a medication called Pregabalin. Each capsule contains 25 mg of the active ingredient. It should be stored at a temperature range of 15°C to 30°C (59°F to 86°F) and dispensed in a tight, child-resistant container. The manufacturer is SciaGen Pharmaceuticals, with an address in Hauppauge, NY. A medication guide should be provided to every patient.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

This text is a prescription information for Pregabalin capsules, which contains 300mg of the medication. It advises to store the medication at 5% temperature with excursions permitted to 15-30°C. The medication should be dispensed in child-resistant containers. The dosage and use information is not available and should be referred to the accompanying prescribing information. The manufacturer is SieGen Pharmaceutical located in Huppuge, W 11788.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

This is a description for Pregahal capsules containing 300mg of pregabalin. The capsules should be stored at a temperature of 25°C (77°F) with excursions of up to 30°C (86°F) permitted. They should be dispensed in tight, child-resistant containers and the appropriate dosage and use of the capsules should be determined by referring to the prescribing information. The product is packaged in a box containing 500 capsules and has been manufactured by ScieGen Pharmaceuticals.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

This is a description for Pregabalin capsules containing 50mg of pregabalin in each capsule. The storage temperature is recommended to be 25°C (77°F) with allowable excursions permitted to 15-30°C (59-86°F). Dispensing should be done in tight child-resistant containers. Dosage and usage information can be found in the accompanying prescribing information and medication guide. The label includes NDC 50228-351-10 and a revision date of 01/16. However, there is some irrelevant text from errors mixed in.*

FDA Label Image

Principal Display Panel (50 mg Capsule Blister Pack Carton)

Store the medication at 25°C (77°F), with excursions permitted up to 30°C (86°F). Dispense the medication in a tight, child-resistant container. Each capsule contains 50mg of pregabalin. Refer to the accompanying prescribing information for dosage and use guidelines. This medication is only available through a prescription. Manufacturer: ScigBen Pharmaceuticals, Inc.*

FDA Label Image

Principal Display Panel (50 mg Capsule Blister Pack)

Each capsule contains 50 mg pregabalin and is stored at 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The medication should be dispensed in tight child-resistant containers with a Medication Guide to each patient. This product is manufactured by SciaGen Pharmaceuticals, Inc. in Hauppauge, NY 11788.*

FDA Label Image

Principal Display Panel (75 mg Capsule Blister Pack Carton)

This is a medication called Pregabalin that comes in capsule form with a dosage of 75mg per capsule. It should be stored at 25° (77°F) in child-resistant containers. The dosage and use information is not available here and it is recommended to refer to the accompanying prescribing information. The medication is manufactured by Siena Pharmaceutical and comes in a 1,000 capsule package. The lot number is 50228-352-10 and the revision date is 01/16.*

FDA Label Image

Principal Display Panel (75 mg Capsule Blister Pack)

This is a prescription drug containing 75 mg of pregabalin per capsule. The capsules should be stored tightly in a child-resistant container at 25°C (77°F), but excursions to 30°C (86°F) are permitted. For dosage and use instructions, refer to the accompanying prescribing information. The medication comes in a bottle with 30 capsules, and its NDC number is 50228-352-30. There is no further information available.*

FDA Label Image

Principal Display Panel (75 mg Capsule Blister Pack)

Each capsule of this medication contains 75mg of pregabalin, identified by NDC 50228-352-90. Pregabalin is used to treat certain types of nerve pain and seizures. It should be stored at a temperature between 15°C to 30°C (59°F to 86°F), in a tight and child-resistant container. This medication should only be dispensed with an accompanying medication guide. This information is manufactured by ScieGen Pharmaceuticals, Inc. in Hauppauge, NY 11788.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

FDA Label Image

Figure 2 (Pregabalin Fig02)

The given text is a table representing the percentage of improvement in pain from the baseline for patients taking Pregabalin 160 mg. The improvement in pain is shown for 100% of patients, representing the effectiveness of this medication. The table also includes some numerical values which are unclear without context. The last row of the table shows the percentage improvement in pain from baseline. The text also includes a mention of "Facebo", which is not relevant to the table or description.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

FDA Label Image

Figure 4 (Pregabalin Fig04)

FDA Label Image

Figure 5 (Pregabalin Fig05)

The text mentions the names and doses of medications, including Fregabalin and Pregataiin, as well as placebo. It also includes a table or graph showing a percentage of patient improvement and the percentage improvement in pain from baseline. However, the text is not clear enough to provide a useful description due to several errors resulting in misspellings and inconsistent formatting.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

This appears to be a table or graph displaying data from various studies with different doses of a medication and placebo. The text shows the dosage ranges used in the studies and suggests that the medication was statistically significant compared to the placebo. The context of the data and medication being studied is not available.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

The text shows a graph of the percent of patients who improved by using Pregabalin 300mg daily dose and Pregabalin 450mg daily dose. The graph compares the improvement in pain from baseline in the two doses of Pregabalin and also includes a placebo. The x-axis shows the percent improvement while the y-axis shows the different doses. No further information or context is given.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

This appears to be a graph showing the estimated percentage of subjects without "LTR" for two groups, one labeled "Progabain" and the other labeled "Placebo". The graph shows percentages ranging from 0% to 100% on the y-axis, and days ranging from 0 to 180 on the x-axis. Without any additional context, it is not possible to determine the meaning of "LTR" or the purpose of the study.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

The text provides a table showing the percentage improvement of subjects from baseline to week 16 for Pregabalin and Placebo. The table shows that the percent of subjects improved was 100%, 210%, 220%, 230%, 240%, 250%, 260%, and 270%. However, the values for Pregabalin and Placebo are not clearly identified, making it difficult to interpret the data accurately.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

This text appears to be a mathematical formula for calculating creatinine clearance (CLCT), a measure of kidney function. It involves subtracting the patient's age (in years) from 140, multiplying by their weight in kilograms, then multiplying by 0.85 for female patients. The result is then multiplied by their serum creatinine level in milligrams per deciliter (mg/dL) and divided by 72. The purpose of this formula is to estimate the rate at which the kidneys are able to filter waste products from the blood.*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.